-
FROM REGULATORY APPROVAL TO PUBLIC REIMBURSEMENT: COVERAGE, ACCESS TIMELINES, AND EXPENDITURE FOR NEW MEDICINE IN TAIWAN
Aug 11, 2026, 17:16 PM -
COST OF PROGRESSION FREE SURVIVAL AND TIME TO NEXT TREATMENT ANALYSIS OF IBRUTINIB PLUS VENETOCLAX AND ACALABRUTINIB PLUS VENETOCLAX IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM FOR PATIENTS WITH UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA
Aug 11, 2026, 17:16 PM -
SHOULD WE COLLECT PATIENT PREFERENCE INSIGHTS IN REGISTRIES? FINDINGS FROM THE PPD COREVITAS OBESITY REGISTRY (OBR)
Aug 11, 2026, 17:16 PM -
MAPPING THE FUTURE OF HEALTH DATA SCIENCE: INSIGHTS FROM AN EXPERT SURVEY
Aug 11, 2026, 17:16 PM -
GENERIC VERSUS HIV-SPECIFIC HEALTH-RELATED QUALITY-OF-LIFE MEASURES: A COMPARATIVE ASSESSMENT OF EQ-5D-5L AND MOS-HIV IN A HIGH HIV PREVALENCE POPULATION IN UGANDA
Aug 11, 2026, 17:16 PM -
CLINICAL AND ECONOMIC EVALUATION OF FARICIMAB FOR DIABETIC MACULAR EDEMA: IMPLICATIONS FOR TREATMENT BURDEN AND HEALTHCARE RESOURCE UTILIZATION IN KAZAKHSTAN
Aug 11, 2026, 17:16 PM -
ACCEPTABILITY OF INDIRECT TREATMENT COMPARISONS IN ORPHAN VERSUS NON-ORPHAN NICE TECHNOLOGY APPRAISALS
Aug 11, 2026, 17:16 PM -
OLDER WOMEN WITH EARLY-STAGE BREAST CANCER: TREATMENT INTENSITY, CENTRALIZATION, AND COMPETING MORTALITY IN CZECH NATIONAL REGISTRIES
Aug 11, 2026, 17:16 PM -
HUMANISTIC BURDEN OF CACHEXIA IN GASTROINTESTINAL CANCERS: A SYSTEMATIC LITERATURE REVIEW
Aug 11, 2026, 17:16 PM -
FROM SURVIVAL EXTRAPOLATION TO COST-EFFECTIVENESS ANALYSIS: A PARTITIONED SURVIVAL MODEL MODULE IN R SHINY
Aug 11, 2026, 17:16 PM -
WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT IN HUNTINGTON'S DISEASE: EVIDENCE FROM THE UK
Aug 11, 2026, 17:16 PM -
PARENT-CHILD AGREEMENT IN PEDIATRIC HRQOL MEASURED BY PEDSQL: DIFFERENCES BY DISEASE CHRONICITY AND CONTEXT
Aug 11, 2026, 17:16 PM -
CHARACTERIZING THE PRE-DIAGNOSTIC WORKUP GAP IN NEWLY DIAGNOSED TESTICULAR CANCER IN MALES AGED 15-45: ANALYSIS OF US REAL-WORLD DATA
Aug 11, 2026, 17:16 PM -
ECONOMIC IMPACT OF EARLY DIAGNOSIS AND IMMUNOGLOBULIN TREATMENT FOR INBORN ERRORS OF IMMUNITY WITH FOCUS ON COMMON VARIABLE IMMUNODEFICIENCY (CVID) IN BRAZIL: A COST-EFFECTIVENESS PERSPECTIVE
Aug 11, 2026, 17:16 PM -
COMPARATOR SELECTION UNDER EU JOINT CLINICAL ASSESSMENT: IMPLICATIONS FOR PICO SCOPING, PICO CONSOLIDATION AND EVIDENCE GENERATION PLANS
Aug 11, 2026, 17:16 PM -
AVAILABILITY AND PRICES OF LOCALLY PRODUCED AND IMPORTED ANTI-CANCER MEDICINES IN PAKISTAN
Aug 11, 2026, 17:16 PM -
HEALTHCARE RESOURCE UTILIZATION AND REAL-WORLD BURDEN OF ILLNESS IN PATIENTS WITH PD-L1-NEGATIVE METASTATIC TRIPLE-NEGATIVE BREAST CANCER IN THE FIRST-LINE SETTING
Aug 11, 2026, 17:16 PM -
GENESIS: AN OBSERVATIONAL DIGITAL STUDY REPORTING GENERAL POPULATION NORMS FOR THE I-RODS, MMN-RODS, CAP-PRI & GO-QOL IN 6 COUNTRIES
Aug 11, 2026, 17:16 PM -
COST-CONSEQUENCE ANALYSIS OF COVERED BALLOON-EXPANDABLE STENTS WITH PUBLISHED 3-YEAR OUTCOMES FOR AORTOILIAC OCCLUSIVE DISEASE IN THE UK
Aug 11, 2026, 17:16 PM -
ARE CURRENT EVIDENCE SYNTHESIS STANDARDS FIT FOR THE EU JOINT CLINICAL ASSESSMENT ERA? GAPS ACROSS PRISMA, COCHRANE, ISPOR, AND HTA GUIDANCE
Aug 11, 2026, 17:16 PM
